ODAN-TIMOLOL SOLUTION

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

TIMOLOL (TIMOLOL MALEATE)

Saatavilla:

ODAN LABORATORIES LTD

ATC-koodi:

S01ED01

INN (Kansainvälinen yleisnimi):

TIMOLOL

Annos:

0.5%

Lääkemuoto:

SOLUTION

Koostumus:

TIMOLOL (TIMOLOL MALEATE) 0.5%

Antoreitti:

OPHTHALMIC

Kpl paketissa:

5ML/10ML/15ML

Prescription tyyppi:

Prescription

Terapeuttinen alue:

BETA-ADRENERGIC AGENTS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0131275002; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2015-10-05

Valmisteyhteenveto

PRODUCT MONOGRAPH
PR
ODAN-TIMOLOL
timolol maleate ophthalmic solution, USP
0 . 2 5 % , 0.5% w/v timolol
Sterile Ophthalmic Solution
Elevated Intraocular Pressure Therapy
ODAN LABORATORIES LTD.
325, Stillview Ave.
Pointe-Claire, QC
H9R 2Y6
Canada
Date of Preparation:
September 22, 2015
SUBMISSION CONTROL NO: 187429
www.odanlab.com
_ODAN-TIMOLOL_
_ _
_Page 2 of 21_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................... 3
SUMMARY PRODUCT INFORMATION
.........................................................................
3
INDICATIONS AND CLINICAL USE
...............................................................................
3
CONTRAINDICATIONS
.....................................................................................................
3
WARNINGS AND PRECAUTIONS
...................................................................................
3
ADVERSE REACTIONS
.....................................................................................................
6
DRUG INTERACTIONS
...................................................................................................
8
DOSAGE AND ADMINISTRATION
.................................................................................
9
OVERDOSAGE
..................................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 10
STORAGE AND STABILITY
...........................................................................................
11
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................. 11
PART II: SCIENTIFIC INFORMATION
..................................................................................
12
PHARMACEUTICAL INFORMATION
...........................................................................
12
CLINICAL TRIALS
........................................................................................